Precisedx Inc.’s digital artificial intelligence (AI) platform better predicts the recurrence of early-stage breast cancer within six years than traditional testing, a study published in Breast Cancer Research found. Understanding which patients with early-stage disease face significant risk of their cancer returning is important for guiding selection of treatment. The system reduces the variability inherent in histological characterization and grading of breast cancer (BC) today, thereby improving prognostic accuracy.
Cells that break away from a tumor and colonize other regions of the body express genes that are different from those of the cancer from which they originate. Now, a Baylor College of Medicine study has found that metastases can be classified into four cancer subtypes regardless of the primary cancer. This finding describes which genes are active in each one, making it possible to establish the most appropriate treatments for each patient according to the subtype of metastasis they have developed.
Ymmunobio AG has secured ownership of neuronal pentraxin receptor (NPTXR) antibodies after the company signed a transfer ownership agreement with Nagoya University for a license to NPTXR antibodies.
Coeptis Therapeutics Holdings Inc. has entered into a sponsored research agreement with the University of Pittsburgh to advance preclinical development of SNAP-CAR T cells targeting HER2, and to explore opportunities to expand the applicability of SNAP-CAR in oncology.
Medshine Discovery Inc. has presented benzylamino tricyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
N6-methyladenosine (m6A) is the most common endogenous modification in eukaryotic RNAs. Researchers are starting to understand the impact of changes in m6A levels on cancer mechanisms, including immune evasion.
RSS
